Individual NIH NRSA Fellowship (F31)

Research Description

Mechanisms of resistance to CDK4/6-MEK inhibitor therapy in MPNSTs

In the Quelle lab, we have justified the use of both CDK4/6 and MEK inhibitors in MPNSTs. Dual targeting of CDK4/6 and MEK induces tumor regression in a de novo mouse models. However, drug resistant tumors emerge in time. Our goal is to elucidate the mechanism that provides MPNSTs with resistance to CDK4/6-MEK inhibition.

Awards

• NIH/NCI Ruth L. Kirschstein National Research Service Award (NRSA), 2023-2026
• Oral Presentation award, Pharmaceutical and Pharmacological Sciences Research Retreat, University of Iowa, 2022
• Fellowship appointment on the Pharmacological Sciences Training Program (NIH T32 GM144636), University of Iowa, 2022-2023
• Fellowship appointment on the Pharmacological Sciences Training Program (NIH T32 GM067795), University of Iowa, 2021-2022